Your trusted guide to clinical trials
Find clinical trials relevant to you, near you. Powered by AI.
Find matching trials effortlessly with your medical profile
Import your Electronic Health Record to browse trials matching your health profile
Browse Trials by Condition
- Neoplasms 14,517
- Carcinoma 6,196
- Pain 2,865
- Surgery 2,691
- Breast Cancer 2,304
- Wounds 2,177
- Cardiac Disease 1,944
- Heart Disease 1,944
- Diabetes Mellitus, Type 2 1,655
- Solid Tumor 1,621
- Depression 1,311
- Metastatic Cancer 1,253
- Neoplasm Metastasis 1,063
- Anxiety Disorders 964
- Vascular Diseases 912
- Dementia 866
- Alzheimer's Disease 866
- Parkinson's Disease 789
- Mild Cognitive Impairment 735
- Esophageal Disorders 723
- Squamous Cell Carcinoma 612
TrialX — your clinical trial finder
A new, easy way to participate in clinical studies.
You are in great company.
Institutes that trust us.
New & updated studies
Browse all studies
Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS
PIONEER-ALS is a Phase 1/2, multicenter, open-label, ascending dose, uncontrolled, first-in-human study that will evaluate the safety, tolerability and effects on clinical and biomarker endpoints of intracisternal administration of Vtx-002 in participants with Amyotrophic Lateral Sclerosis (ALS). Two escalating dose (low dose and high dose) cohorts are planned. The duration …
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
The purpose of this phase Ib/II study is to (a) in Phase Ib evaluate the safety, tolerability, and pharmacokinetics (PK) of AMO959 when given in combination with lutetium (177Lu) vipivotide tetraxetan (also known as \[177Lu\]Lu-PSMA-617 or 177Lu-PSMA-617 and hereafter referred to as AAA617) with an androgen receptor pathway inhibitor (ARPI) …
A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)
Researchers are looking for new ways to treat high-risk non-muscle invasive bladder cancer (HR NMIBC). NMIBC is cancer in the tissue that lines the inside of the bladder and has not spread to the bladder muscle or outside of the bladder. In standard treatment for HR NMIBC, doctors first remove …
A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CROSSOVER STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 μG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF OCULAR GRAFT-VERSUS-HOST DISEASE (OGVHD)
An 84-day, prospective, randomized (1:1) vehicle controlled, double-masked pre-market, crossover study. Subjects with moderate to severe oGVHD related Dry Eye Disease Each subject will receive both treatments in random sequence, each for 28 days, separated by a 14-day vehicle washout period.
PULSAR in Systemic Therapy for Pancreatic Cancer
Pancreatic cancer remains one of the malignancies with the lowest survival rates, largely due to late-stage diagnosis and the difficulty of achieving curative resection. A substantial proportion of patients present with locally advanced, unresectable disease at the time of diagnosis, making intensive systemic therapy the current standard of care. For …
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
For patients with breast cancer, it's important to find any remaining cancer cells after they've had their main treatment. Even a few cells, called minimal residual disease (MRD), can lead to the cancer coming back later. A way to find these cells is by looking for tiny bits of cancer …
Your clinical trial journey
Find a study
Search or browse for a clinical trial near you.
Check Eligibility
Learn more about the trial and check to see if you are eligible to take part in it.
Participate
If you prequalify, connect with the study team and let your trial journey begin!
Accelerating clinical research powered by AI
Building patient connection for a better future
Join us in our mission to help accelerate clinical research.
We are on a mission to make 1 billion actions made towards clinical research. ‘Actions’ are anything from searching for trials, sharing a trial, getting in touch with a study team — or something as simple as becoming a volunteer.